research collaborations. Its research and development efforts center on precision-targeted biologics designed to address unmet needs in patients who have exhausted existing treatment options. Ona Therapeutics maintains a pipeline of oncology programs, including ADC candidates for breast cancer and other solid tumors, and applies antibody engineering and target validation approaches to support therapeutic development. The company also profiles target expression in both healthy and cancerous tissues to guide the design and selection of its drug candidates.